I. Fernández

A phase II randomized trial of gemcitabine-docetaxel versus gemcitabine-cisplatin in patients with advanced non-small cell lung carcinoma

M. Lázaro, F. Vázquez, G. Alonso, 2009, Cancer Chemotherapy and Pharmacology.

Anti-HER2 Therapy Beyond Second-Line for HER2- Positive Metastatic Breast Cancer: A Short Review and Recommendations for Several Clinical Scenarios from a Spanish Expert Panel

S. Servitja, A. de Juan, P. Zamora, 2016, Breast Care.

GEINOFOTE: efficacy and safety of fotemustine in patients with high-grade recurrent gliomas and poor performance status

P. Pérez-Segura, V. Moreno, M. Benavides, 2016, Clinical and Translational Oncology.

SEOM—GECOD clinical guideline for unknown primary cancer (2021)

O. Etxaniz, G. Soler, F. Longo, 2022, Clinical and Translational Oncology.

Phase III Trial of Adjuvant Capecitabine After Standard Neo-/Adjuvant Chemotherapy in Patients With Early Triple-Negative Breast Cancer (GEICAM/2003-11_CIBOMA/2004-01)

H. Gómez, A. Guerrero-Zotano, A. Lluch, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Quality of life with palbociclib plus fulvestrant versus placebo plus fulvestrant in postmenopausal women with endocrine-sensitive hormone receptor-positive and HER2-negative advanced breast cancer: patient-reported outcomes from the FLIPPER trial

J. Albanell, M. Ramos, M. Casas, 2023, Therapeutic advances in medical oncology.

Bevacizumab and temozolomide versus temozolomide alone as neoadjuvant treatment in unresected glioblastoma: the GENOM 009 randomized phase II trial

J. J. de la Cruz, C. Balañà, M. Martínez-García, 2016, Journal of Neuro-Oncology.